Matching articles for "Gohibic"

COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023;  (Issue 1677)
The investigational anti-complement component 5a (C5a) antibody vilobelimab (Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with...
The investigational anti-complement component 5a (C5a) antibody vilobelimab (Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with COVID-19 beginning within 48 hours after invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) is started. Vilobelimab is the first anti-C5a antibody to become available in the US.
Med Lett Drugs Ther. 2023 May 29;65(1677):86-7 | Show Full IntroductionHide Full Introduction